JP2008539267A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539267A5
JP2008539267A5 JP2008509128A JP2008509128A JP2008539267A5 JP 2008539267 A5 JP2008539267 A5 JP 2008539267A5 JP 2008509128 A JP2008509128 A JP 2008509128A JP 2008509128 A JP2008509128 A JP 2008509128A JP 2008539267 A5 JP2008539267 A5 JP 2008539267A5
Authority
JP
Japan
Prior art keywords
compound according
och
formula
carbon
attached form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008509128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/016057 external-priority patent/WO2006116614A1/en
Publication of JP2008539267A publication Critical patent/JP2008539267A/ja
Publication of JP2008539267A5 publication Critical patent/JP2008539267A5/ja
Pending legal-status Critical Current

Links

JP2008509128A 2005-04-26 2006-04-26 ベンズイソオキサゾールピペリジン化合物及びその使用方法 Pending JP2008539267A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67520205P 2005-04-26 2005-04-26
PCT/US2006/016057 WO2006116614A1 (en) 2005-04-26 2006-04-26 Benzisoxazole piperidine compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2008539267A JP2008539267A (ja) 2008-11-13
JP2008539267A5 true JP2008539267A5 (https=) 2012-12-06

Family

ID=36754209

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008509129A Expired - Fee Related JP5049267B2 (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペラジン化合物およびその使用方法
JP2008509128A Pending JP2008539267A (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペリジン化合物及びその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008509129A Expired - Fee Related JP5049267B2 (ja) 2005-04-26 2006-04-26 ベンズイソオキサゾールピペラジン化合物およびその使用方法

Country Status (15)

Country Link
US (3) US8129410B2 (https=)
EP (2) EP1877405B1 (https=)
JP (2) JP5049267B2 (https=)
CN (1) CN101208314B (https=)
AT (2) ATE459621T1 (https=)
AU (1) AU2006239302B2 (https=)
CA (2) CA2606473C (https=)
CY (1) CY1110026T1 (https=)
DE (2) DE602006012650D1 (https=)
DK (1) DK1877390T3 (https=)
ES (2) ES2341127T3 (https=)
MX (1) MX2007013352A (https=)
PL (1) PL1877390T3 (https=)
PT (1) PT1877390E (https=)
WO (1) WO2006116614A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
JP5049267B2 (ja) * 2005-04-26 2012-10-17 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法
JP5286254B2 (ja) 2006-05-18 2013-09-11 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (es) * 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
US9220837B2 (en) * 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
EP2136863A2 (en) * 2007-03-19 2009-12-30 Insuline Medical Ltd. Device for drug delivery and associated connections thereto
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20090263449A1 (en) * 2008-04-09 2009-10-22 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN104739829B (zh) 2008-10-28 2018-11-06 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8565107B2 (en) 2010-09-24 2013-10-22 Hand Held Products, Inc. Terminal configurable for use within an unknown regulatory domain
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
KR102823056B1 (ko) 2019-06-18 2025-06-23 화이자 인코포레이티드 벤즈이속사졸 설폰아마이드 유도체
PT4082616T (pt) * 2019-12-24 2025-12-02 Sumitomo Pharma Co Ltd Derivado de amida ácida alifática
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331541A (en) * 1965-06-07 1967-07-18 Bell & Howell Co Sprocketless projector
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
FR2654104B1 (fr) 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
FR2742052B1 (fr) 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
WO1997049698A1 (en) 1996-06-21 1997-12-31 Glaxo Group Limited Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders
US6498251B1 (en) * 1997-12-25 2002-12-24 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole derivatives
US6331541B1 (en) * 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
ATE455108T1 (de) 2001-02-16 2010-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
ES2201899B1 (es) * 2002-04-01 2005-06-01 Almirall Prodesfarma, S.A. Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
JP5049267B2 (ja) * 2005-04-26 2012-10-17 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法

Similar Documents

Publication Publication Date Title
JP2008539267A5 (https=)
JP2008539268A5 (https=)
JP2010500293A5 (https=)
JP2010529118A5 (https=)
JP2015505296A5 (https=)
JP2012532874A5 (https=)
JP2006143751A5 (https=)
JP2010077141A5 (https=)
JP2010509379A5 (https=)
JP2010524932A5 (https=)
JP2013519675A5 (https=)
JP2014518266A5 (https=)
JP2013525444A5 (https=)
JP2009502743A5 (https=)
JP2009507909A5 (https=)
JP2010540509A5 (https=)
JP2013509429A5 (https=)
JP2011523412A5 (https=)
JP2013508279A5 (https=)
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
JP2014530900A5 (https=)
JP2010504343A5 (https=)
JP2008513510A5 (https=)
JP2013514980A5 (https=)
JP2010518061A5 (https=)